{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"}]}],"title":"Percentage of Participants with AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"48"}]}],"title":"Percentage of Participants with SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"An AE is any unfavourable and unintended sign (including abnormal laboratory finding), symptom, or disease temporarily associated with the use of a study drug, whether or not considered related to the study drug. A SAE is any experience that results in death, is life-threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically significant.","groups":[{"description":"Participants received rituximab as an intravenous (IV) infusion of 375 milligrams per metre squared (mg/m\\^2) once a week on Days 1, 8, 15 and 22 during Remission Induction Phase (Day 1 (baseline) to Month 6)","id":"OG000","title":"Remission Induction Phase (up to 6 Mos.) Rituximab"},{"description":"Participants who received rituximab during the Remission Induction Phase were followed for a minimum of 18 months during the Follow-up Phase and could receive additional rituximab or other treatments for GPA/MPA (Day 1 (baseline) up to 4.5 yrs)","id":"OG001","title":"Overall Follow-up Phase (up to 4.5 Yrs) Rituximab"}],"paramType":"NUMBER","populationDescription":"The safety population included all participants who received at least part of one infusion of rituximab.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) up to last visit (1.5-5 years)","title":"Percentage of Participants With Adverse Events (AEs), Including Serious AEs","type":"PRIMARY","unitOfMeasure":"percentage of participants"}